3491. Adulteration and misbranding of Conjugestoral tablets (conjugated estrogens). U. S. v. 2 Bottles * * *. (F. D. C. No. 30918. Sample No. 5010–L.)

LIBEL FILED: April 13, 1951, District of Massachusetts.

ALLEGED SHIPMENT: On or about October 9 or 14, 1950, by the Corby-Franklin Associates, from New York, N. Y.

PRODUCT: 2 1,000-tablet bottles of *Conjugestoral tablets* (conjugated estrogens) at Boston, Mass. Analyses showed that the product contained a total amount of estrogenic steriods calculated to 0.34 mg. of sodium estrone sulfate per tablet.

LABEL, IN PART: "Tablets Conjugestoral (Conjugated Estrogens)."

NATURE OF CHARGE: Adulteration, Section 501 (c), the strength of the article differed from that which it was represented to possess, namely, "1.25 mgm. of Estrogens in their naturally occurring water soluble conjugated form expressed as sodium estrone sulfate."

Misbranding, Section 502 (a), the label statement "Each tablet contains 1.25 mgm. of Estrogens in their naturally occurring water soluble conjugated form expressed as sodium estrone sulfate" was false and misleading as applied to the product, which contained less than the stated amount of estrogens.

DISPOSITION: May 21, 1951. Default decree of condemnation and destruction.

3492. Adulteration and misbranding of mephenesin. U. S. v. 4 Bottles * * *. (F. D. C. No. 31029. Sample No. 17260–L.)

LIBEL FILED: May 1, 1951, Southern District of California.

ALLEGED SHIPMENT: On or about January 9, 1951, from Long Island City, N. Y., to Modern Medicals, Inc., Los Angeles, Calif.

PRODUCT: 4 1,000-capsule bottles of *mephenesin* at Los Angeles, Calif. After shipment in interstate commerce, Modern Medicals, Inc., repackaged the product in capsule form, relabeled it, and delivered the product to the person in whose possession it was at the time of seizure. Examination showed that the product contained an average of 0.166 grams of mephenesin per capsule.

NATURE OF CHARGE: Adulteration, Section 501 (c), the strength of the article differed from that which it purported and was represented to possess.

Misbranding, Section 502 (a), the label designation "Mephenesin 0.25 grams" was false and misleading as applied to an article which contained less than the stated amount of mephenesin per capsule.

The article was adulterated and misbranded in the above respects while held for sale after shipment in interstate commerce.

DISPOSITION: May 23, 1951. Default decree of condemnation and destruction.

3493. Adulteration and misbranding of sodium salicylate tablets. U. S. v. 1 Drum * * *. (F. D. C. No. 30892. Sample No. 25383–L.)

LIBEL FILED: April 4, 1951, Eastern District of Pennsylvania.

ALLEGED SHIPMENT: On or about March 12, 1951, by Morse Laboratories, Inc., from New York, N. Y.